Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France. Show more
Location: 50 rue de Dijon, Daix, 21121, France | Website: https://inventivapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
606.8M
52 Wk Range
$2.11 - $7.98
Previous Close
$4.16
Open
$4.04
Volume
92,316
Day Range
$3.90 - $4.19
Enterprise Value
743.4M
Cash
122.5M
Avg Qtr Burn
-22.83M
Insider Ownership
0.00%
Institutional Own.
5.18%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Lanifibranor (Pan-PPAR) Details Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 Data readout | |
Lanifibranor + empagliflozin Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes | Phase 2a Update | |
Cedirogant (ABBV-157) (60RORy) Details Psoriasis, Kidney cancer, Carcinoma | Failed Discontinued | |
Odiparcil (GAG) Details Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder | Failed Discontinued |
